Whittier Trust Co. Acquires 1,235 Shares of West Pharmaceutical Services Inc. (NYSE:WST)

Whittier Trust Co. boosted its holdings in West Pharmaceutical Services Inc. (NYSE:WST) by 4.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,925 shares of the medical instruments supplier’s stock after buying an additional 1,235 shares during the quarter. Whittier Trust Co.’s holdings in West Pharmaceutical Services were worth $3,745,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Hoover Financial Advisors Inc. raised its holdings in West Pharmaceutical Services by 0.3% in the 1st quarter. Hoover Financial Advisors Inc. now owns 42,208 shares of the medical instruments supplier’s stock valued at $4,651,000 after buying an additional 107 shares during the last quarter. Zions Bancorporation N.A. raised its holdings in West Pharmaceutical Services by 3.0% in the 2nd quarter. Zions Bancorporation N.A. now owns 5,242 shares of the medical instruments supplier’s stock valued at $656,000 after buying an additional 155 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in West Pharmaceutical Services by 0.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 42,374 shares of the medical instruments supplier’s stock valued at $4,154,000 after buying an additional 159 shares during the last quarter. Crossmark Global Holdings Inc. raised its holdings in West Pharmaceutical Services by 2.1% in the 1st quarter. Crossmark Global Holdings Inc. now owns 7,636 shares of the medical instruments supplier’s stock valued at $841,000 after buying an additional 160 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in West Pharmaceutical Services by 1.0% in the 1st quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the medical instruments supplier’s stock valued at $2,193,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. William Blair initiated coverage on shares of West Pharmaceutical Services in a research report on Tuesday, April 23rd. They set an “outperform” rating and a $112.16 target price for the company. Jefferies Financial Group downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 target price for the company. in a research report on Wednesday, May 1st. Finally, Bank of America raised shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. West Pharmaceutical Services has an average rating of “Hold” and a consensus price target of $123.05.

NYSE:WST traded down $1.72 on Friday, reaching $135.56. 322,850 shares of the stock traded hands, compared to its average volume of 339,073. The stock has a market capitalization of $10.12 billion, a price-to-earnings ratio of 48.24, a price-to-earnings-growth ratio of 3.91 and a beta of 1.30. The firm has a 50 day moving average of $125.39. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.02 and a quick ratio of 2.13. West Pharmaceutical Services Inc. has a 1-year low of $91.75 and a 1-year high of $139.59.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.17. The business had revenue of $469.70 million during the quarter, compared to the consensus estimate of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.70 EPS. On average, sell-side analysts predict that West Pharmaceutical Services Inc. will post 3.07 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 6th. Shareholders of record on Wednesday, October 23rd will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Tuesday, October 22nd. West Pharmaceutical Services’s dividend payout ratio is presently 21.35%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: Do investors pay a separate front-end load every time they buy additional shares?

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.